(RTTNews.com) – Amgen Inc. ( AMGN ) announced formula from a Repatha or evolocumab cognitive duty hearing (EBBINGHAUS) evaluating a impact on cognitive duty in 1,974 patients enrolled in a Repatha cardiovascular outcomes study, FOURIER.
The investigate demonstrated that a outcome of Repatha on a primary endpoint of executive duty was non-inferior to placebo.
In addition, Amgen remarkable that there was no statistical disproportion between Repatha and remedy on a other cognitive domains tested: operative memory, memory duty and psychomotor speed – a delegate endpoints.
Amgen presented a minute formula from EBBINGHAUS during a Late-Breaking Clinical Trials Session during a American College of Cardiology 66th Annual Scientific Session in Washington, D.C.
For comments and feedback: hit firstname.lastname@example.org